The Phase 2b trial is definitely a multicenter, randomized, double-blind, placebo-controlled research in HIV infected patients receiving antiretroviral therapy to evaluate the efficacy and protection of AGS-004 when compared to placebo during an analytical treatment interruption of ART.D., basic principle investigator of the scholarly study at Drexel University in Philadelphia. A total of 42 patients are expected to be signed up for the Stage 2b trial. Nine sites in THE UNITED STATES are participating in the trial, which is normally funded by the National Institutes of Wellness, as part of a $28 million contract that Argos was awarded in 2006. The Phase 2b trial will further demonstrate that AGS-004 is an effective and safe option treatment for HIV individuals, stated Jeff Abbey, president and ceo of Argos.In 2012, there have been around 207 million situations of malaria and 627,000 deaths worldwide, among African children mostly. Low-cost solutions to avoid the disease include interior or LLINs residual spraying, that involves spraying insecticide on roofs and walls where mosquitoes will probably land. Both have been proven to reduce the amount of deaths because of malaria. But, until now, there’s been little evidence to handle whether merging these interventions would provide greater results.